UK Authorizes Vertex’s Casgevy, The World’s First CRISPR/Cas9 Gene Therapy
Vertex’s Casgevy has made history as the world’s first approved CRISPR gene editing therapy after the UK’s MHRA authorized the medicine ahead of its US and European regulatory counterparts.
You may also be interested in...
Julie Tierney will become CBER’s deputy director for strategy, policy and legislation, a newly created position.
Great Britain is first to approve the groundbreaking CRISPR-based therapy for sickle cell and beta thalassemia. Vertex is yet to reveal its price, however, and wants to play down early expectations of its commercial potential.
Three orphan drugs were among the eight products recommended for pan-EU marketing approval by the European Medicines Agency this week, while Novartis withdrew its filing for Vijoice.